For 2025, the company is now guiding adjusted income from operations guidance to between $2.151B to $2.155B on revenue in the ...

Investing.com -- Federal Reserve Governor Lisa Cook indicated Monday that the December Fed meeting is "live" for a potential ...

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 22% after the company announced that its ESSENCE study for ultra-rare disease therapies AMONDYS 45 and VYONDYS 53 failed to achieve ...

Investing.com -- Navitas Semiconductor (NASDAQ:NVTS) shares tumbled 8.2% in after-hours trading Monday after the next-generation power semiconductor company reported third-quarter results that missed ...

Investing.com -- Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares tumbled 9.2% in after-hours trading Monday after the commercial-stage biopharmaceutical company reported third-quarter revenue that ...

Much of the economic uncertainty regarding tariffs is now over, since President Trump wrapped up major trade deals on his recent Asia trip. We are now in the midst of accelerating GDP growth, with ...

Silver mining stocks have shown remarkable strength throughout 2025, with several companies capitalizing on favorable market conditions. Using a combination of fair value assessments, Pro scores, ...

Investing.com -- Boqii Holding Ltd (NYSE:BQ) stock tumbled 16.8% on Monday after the pet-focused platform announced a registered direct offering that would raise approximately $4.2 million but dilute ...

"While the ESSENCE study did not meet statistical significance on its primary endpoint, we believe the results demonstrated a clear treatment effect, showing clinically meaningful functional outcomes ...

Investing.com -- IAC (NASDAQ:IAC) shares plunged 11.9% in after-hours trading Monday after the digital media company reported third-quarter results that missed analyst expectations, with revenue ...

Diamondback maintained its commitment to shareholder returns, declaring a base cash dividend of $1.00 per share for the third quarter. The company also repurchased approximately 4.3 million shares for ...

Following the strong performance, Exact Sciences raised its full-year 2025 guidance, now expecting revenue between $3.22 billion and $3.235 billion, above the previous consensus of $3.157 billion. The ...